• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (107)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Rheumatology  • Osteoporosis  • Drug Therapy  • Adverse Effects  • Endocrine Diseases  • Diabetes Mellitus  • Alert me on articles by topic  Social Bookmarking   What's this?

Arch Intern Med. 2008;168(8):820-825.

Background  Thiazolidinediones may adversely affect the skeleton owing to decreased bone formation and accelerated bone loss.

Methods  This study examines the association between the use of thiazolidinediones or other oral antidiabetic drugs and the risk of fracture. This nested case-control analysis uses the UK General Practice Research Database, including case patients with fracture aged 30 to 89 years with an incident fracture diagnosis between January 1994 and December 2005 and control subjects who were matched to case patients on age, sex, calendar time, and general practice attended. We assessed the odds ratios (ORs) of having a fracture associated with the use of rosiglitazone maleate, pioglitazone hydrochloride, other oral antidiabetic agents, or insulin.

Results  There were 1020 case patients with an incident low-trauma fracture and 3728 matched controls. After adjustment for age, body mass index, other antidiabetic drugs, comedication, and comorbidities, the ORs for users of 8 or more thiazolidinedione prescriptions (corresponding to approximately 12-18 months of therapy) compared with nonuse was 2.43 (95% confidence interval [CI], 1.49-3.95). Rosiglitazone (OR, 2.38; 95% CI, 1.39-4.09) and pioglitazone (OR, 2.59; 95% CI, 0.96-7.01) were used more frequently by case patients with fracture (predominantly hip and wrist fractures) than by controls. The association was independent of patient age and sex and tended to increase with thiazolidinedione dose. No materially altered relative fracture risk was found in association with the use of other oral antidiabetic drugs.

Conclusion  This analysis provides further evidence of a possible association between long-term use of thiazolidinediones and fractures, particularly of the hip and wrist, in patients with diabetes mellitus.

Author Affiliations: Division of Endocrinology, Diabetes, and Clinical Nutrition (Drs C. Meier and Kraenzlin) and Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology and Toxicology (Drs Bodmer and C. R. Meier), University Hospital Basel, Basel, Switzerland; and Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, Lexington, Massachusetts, and Department of Epidemiology, School of Public Health, Boston University, Boston, Massachusetts (Drs S. S. Jick, H. Jick, and C. R. Meier).

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Considering Competing Risks . . . Not All Black and White
Jane A. Cauley and Kristine E. Ensrud
Arch Intern Med. 2008;168(8):793-795.
EXTRACT | FULL TEXT  

Use of Alendronate and Risk of Incident Atrial Fibrillation in Women
Susan R. Heckbert, Guo Li, Steven R. Cummings, Nicholas L. Smith, and Bruce M. Psaty
Arch Intern Med. 2008;168(8):826-831.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Use of Metformin Is Not Associated with a Decreased Risk of Colorectal Cancer: A Case-Control Analysis
Bodmer et al.
Cancer Epidemiol. Biomarkers Prev. 2012;21:280-286.
ABSTRACT | FULL TEXT  

Effects of Pioglitazone on Renal Calcium Excretion
Zanchi et al.
J. Clin. Endocrinol. Metab. 2011;96:E1482-E1485.
ABSTRACT | FULL TEXT  

The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis
Van Wagner and Rinella
Therapeutic Advances in Gastroenterology 2011;4:249-263.
ABSTRACT  

Association of BMD and FRAX Score With Risk of Fracture in Older Adults With Type 2 Diabetes
Schwartz et al.
JAMA 2011;305:2184-2192.
ABSTRACT | FULL TEXT  

Type 2 Diabetes: Uses of thiazolidinediones and insulin
T. Bloomgarden
Diabetes Care 2011;34:e11-e16.
FULL TEXT  

Differential Effects of PPAR-{gamma} Activation versus Chemical or Genetic Reduction of DPP-4 Activity on Bone Quality in Mice
Kyle et al.
Endocrinology 2011;152:457-467.
ABSTRACT | FULL TEXT  

Use of Depot Medroxyprogesterone Acetate and Fracture Risk
Meier et al.
J. Clin. Endocrinol. Metab. 2010;95:4909-4916.
ABSTRACT | FULL TEXT  

Thiazolidinediones and Fractures: Evidence from Translating Research into Action for Diabetes
Bilik et al.
J. Clin. Endocrinol. Metab. 2010;95:4560-4565.
ABSTRACT | FULL TEXT  

Approach to the patient with secondary osteoporosis
Hofbauer et al.
Eur J Endocrinol 2010;162:1009-1020.
ABSTRACT | FULL TEXT  

Long-Term Metformin Use Is Associated With Decreased Risk of Breast Cancer
Bodmer et al.
Diabetes Care 2010;33:1304-1308.
ABSTRACT | FULL TEXT  

PPAR{gamma}, an Essential Regulator of Bone Mass: Metabolic and Molecular Cues
Lecka-Czernik
IBMS BoneKEy 2010;7:171-181.
ABSTRACT | FULL TEXT  

Diabetes Medications Related to an Increased Risk of Falls and Fall-Related Morbidity in the Elderly
Berlie and Garwood
The Annals of Pharmacotherapy 2010;44:712-717.
ABSTRACT | FULL TEXT  

Thiazolidinedione Use and the Longitudinal Risk of Fractures in Patients with Type 2 Diabetes Mellitus
Habib et al.
J. Clin. Endocrinol. Metab. 2010;95:592-600.
ABSTRACT | FULL TEXT  

Germline deletion of AMP-activated protein kinase {beta} subunits reduces bone mass without altering osteoclast differentiation or function
Quinn et al.
FASEB J. 2010;24:275-285.
ABSTRACT | FULL TEXT  

Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database
Tzoulaki et al.
BMJ 2009;339:b4731-b4731.
ABSTRACT | FULL TEXT  

Increased Lipid Oxidation Causes Oxidative Stress, Increased Peroxisome Proliferator-activated Receptor-{gamma} Expression, and Diminished Pro-osteogenic Wnt Signaling in the Skeleton
Almeida et al.
J. Biol. Chem. 2009;284:27438-27448.
ABSTRACT | FULL TEXT  

Thiazolidinediones and Fractures in Men and Women
Dormuth et al.
Arch Intern Med 2009;169:1395-1402.
ABSTRACT | FULL TEXT  

A Cohort Study of Thiazolidinediones and Fractures in Older Adults with Diabetes
Solomon et al.
J. Clin. Endocrinol. Metab. 2009;94:2792-2798.
ABSTRACT | FULL TEXT  

Skeletal Consequences of Deletion of Steroid Receptor Coactivator-2/Transcription Intermediary Factor-2
Modder et al.
J. Biol. Chem. 2009;284:18767-18777.
ABSTRACT | FULL TEXT  

Bone Disease, Gestational Diabetes Mellitus, and Health Care
Bloomgarden
Diabetes Care 2009;32:e77-e83.
FULL TEXT  

MBX-102/JNJ39659100, a Novel Peroxisome Proliferator-Activated Receptor-Ligand with Weak Transactivation Activity Retains Antidiabetic Properties in the Absence of Weight Gain and Edema
Gregoire et al.
Mol. Endocrinol. 2009;23:975-988.
ABSTRACT | FULL TEXT  

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
Loke et al.
CMAJ 2009;180:32-39.
ABSTRACT | FULL TEXT  

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
Nathan et al.
Clin. Diabetes 2009;27:4-16.
FULL TEXT  

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
Nathan et al.
Diabetes Spectr. 2009;22:6-17.
FULL TEXT  

Thiazolidinediones and cardiovascular outcomes in type 2 diabetes
Singh and Furberg
Heart 2009;95:1-3.
FULL TEXT  

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
Nathan et al.
Diabetes Care 2009;32:193-203.
ABSTRACT | FULL TEXT  

Metformin, Sulfonylureas, or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or Hypoglycemia: A nested case-control analysis
Bodmer et al.
Diabetes Care 2008;31:2086-2091.
ABSTRACT | FULL TEXT  

Thiazolidinediones and Fracture Risk in Diabetic Women
JWatch Women's Health 2008;2008:3-3.
FULL TEXT  

Thiazolidinediones and Risk for Fractures
JWatch General 2008;2008:1-1.
FULL TEXT  

Considering Competing Risks . . . Not All Black and White
Cauley and Ensrud
Arch Intern Med 2008;168:793-795.
FULL TEXT